Adagrasib Plus Cetuximab May Provide Clinical Benefit in Patients with KRASG12C-Mutated Colorectal Cancer

A combination of the KRASG12C inhibitor adagrasib (Krazati) and the anti-epidermal growth factor receptor (EGFR) antibody cetuximab (Erbitux) showed clinical activity and promising survival outcomes in a cohort of patients with metastatic, heavily pretreated, KRASG12C-mutated colorectal cancer, according to results from the phase I/II KRYSTAL-1 trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10 in San Diego. The study was simultaneously published in Cancer Discovery.

Login Or Register To Read Full Story